26,280 Shares in Haemonetics Corporation $HAE Acquired by Nierenberg Investment Management Company LLC

Nierenberg Investment Management Company LLC purchased a new position in Haemonetics Corporation (NYSE:HAE) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 26,280 shares of the medical instruments supplier’s stock, valued at approximately $1,971,000,000. Haemonetics accounts for 1.0% of Nierenberg Investment Management Company LLC’s portfolio, making the stock its 15th biggest holding. Nierenberg Investment Management Company LLC owned about 0.06% of Haemonetics at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. EverSource Wealth Advisors LLC raised its stake in shares of Haemonetics by 12.3% during the first quarter. EverSource Wealth Advisors LLC now owns 1,920 shares of the medical instruments supplier’s stock valued at $108,000 after purchasing an additional 211 shares during the period. Quantinno Capital Management LP boosted its stake in shares of Haemonetics by 9.0% in the second quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock valued at $261,000 after purchasing an additional 289 shares during the period. UMB Bank n.a. boosted its stake in shares of Haemonetics by 110.9% in the fourth quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 306 shares during the period. Cardinal Capital Management grew its holdings in Haemonetics by 1.5% during the 4th quarter. Cardinal Capital Management now owns 22,442 shares of the medical instruments supplier’s stock valued at $1,799,000 after purchasing an additional 321 shares in the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new stake in Haemonetics during the 4th quarter worth $26,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics News Summary

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: New CSL Plasma supply agreement: Haemonetics signed a non-exclusive agreement to supply CSL Plasma’s U.S. collection operations. The deal restores business with a major customer after a prior supply transition weighed on results, potentially improving revenue visibility and supporting the company’s plasma-collection franchise. Haemonetics reconnects with CSL in US plasma collection deal
• Positive Sentiment: Raised fiscal 2027 outlook and solid quarterly results: Haemonetics reported quarterly revenue of $339.4 million, up approximately 5.6% year over year, while adjusted EPS rose to $1.14 and exceeded consensus. Management raised its full-year reported revenue-growth forecast to 5%–8% from 4%–7%, with plasma revenue and adoption of Persona PLUS on the NexSys PCS platform providing momentum. Haemonetics Jumps as Investors Cheer Raised Fiscal 2027 Outlook
• Positive Sentiment: Analyst support: BTIG raised its price target from $96 to $110 and maintained a Buy rating, reinforcing bullish momentum. BTIG raises Haemonetics price target

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Raymond James Financial reiterated an “outperform” rating and issued a $105.00 price objective on shares of Haemonetics in a report on Friday, August 7th. Wall Street Zen upgraded Haemonetics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Mizuho lifted their target price on Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Weiss Ratings upgraded Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Finally, Bank of America raised Haemonetics from a “neutral” rating to a “buy” rating and increased their price target for the company from $72.00 to $80.00 in a report on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $95.00.

Haemonetics Trading Up 3.6%

HAE opened at $108.39 on Thursday. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $108.50. The company has a debt-to-equity ratio of 1.40, a current ratio of 3.08 and a quick ratio of 1.91. The stock has a market capitalization of $4.93 billion, a PE ratio of 53.14, a P/E/G ratio of 2.10 and a beta of 0.52. The firm’s fifty day moving average price is $80.50 and its 200 day moving average price is $67.90.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.06. The company had revenue of $339.38 million during the quarter, compared to analyst estimates of $327.86 million. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period last year, the business earned $1.10 EPS. As a group, research analysts expect that Haemonetics Corporation will post 5.28 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.